The discovery and subsequent introduction of dantrolene in 1979 was a major breakthrough in the treatment of malignant hyperthermia (MH) that is responsible for saving hundreds, if not thousands, of lives. However, one of the major challenges in the successful treatment of MH is the need for rapid mixing, suspension, and administration of dantrolene during a crisis.
Eagle Pharmaceuticals, Inc. today announced the U. S. Food and Drug Administration (FDA) has approved Ryanodex® (dantrolene sodium) for injectable suspension indicated for the treatment of malignant hyperthermia (MH), along with the appropriate supportive measures. MH is an inherited and potentially fatal disorder triggered by certain anesthesia agents in genetically susceptible individuals. FDA had designated Ryanodex as an Orphan Drug in August 2013. Eagle has been informed by the FDA that it will learn over the next four to six weeks if it has been granted the seven year Orphan Drug market exclusivity.
MARSHALL, Illinois - The Geoffrey Keller Memorial Open Water Swim held in honor of the late son of Curt and Kathleen Keller to raise funds to research better ways of managing Malignant Hyperthermia (MH) during surgery, to improve methods of detecting MH, and for MH awareness.
MedicAlert Foundation is pleased to announce that individuals living with Malignant Hyperthermia (MH) are now eligible to receive free medical IDs and live 24/7 emergency response services as the result of a grant obtained through the Sandi Ida Glickstein Fund at the Malignant Hyperthermia Association of the United States (MHAUS).
The Society of Ambulatory Anesthesia (SAMBA) has partnered with the Malignant Hyperthermia Association of the United States (MHAUS) to offer MHAUS membership benefits to active SAMBA members at a reduced rate.
The Geoffrey Keller Memorial Open Water Swim held in honor of the late son of Curt and Kathy Keller to raise funds to research better ways of managing Malignant Hyperthermia during surgery, to improve methods of detecting MH, and for MH awareness. Presented by Marshall, IL, the Geoff Keller Group of MHAUS, and Illinois Department of Natural Resources.
The American Association of Nurse Anesthetists (AANA) has partnered with the Malignant Hyperthermia Association of the United States (MHAUS) to offer MHAUS membership benefits at a reduced rate to Certified Registered Nurse Anesthetists who are active members of the AANA.
A substantial number of patients receive care in ambulatory surgical centers. Experts say storing the drug dantrolene at ambulatory surgical centers will save lives and is very cost effective.
If you are affected by Malignant Hyperthermia, Congenital Muscular Dystrophies or Congenital Myopathy Subtypes, the Malignant Hyperthermia Association of the United States and the Cure Congenital Muscle Disease organization are asking for your help to enable research and clinical trials by registering with the Congenital Muscle Disease International Registry (CMDIR).
March to be Malignant Hyperthermia Awareness and Training Month reminds us that a Malignant Hyperthermia crisis is best managed with preparation. Malignant Hyperthermia is often experienced in individuals undergoing, what was expected to be, routine surgery but can also happen to a person outside of the operating room. Malignant Hyperthermia is a genetic disorder found in an estimated 1 out of 2,000 people. Once triggered, the rapid progressive series of chain events include a body temperature of up to 107 degrees, muscle rigidity, system-wide organ failure, and possible death. Introduction of a treatment drug and advances in the understanding of MH have saved many lives since the syndrome was first described in the 1960s.
The Association of PeriOperative Registered Nurses (AORN) has partnered with the Malignant Hyperthermia Association of the United States (MHAUS) to offer MHAUS membership benefits to active AORN members for a reduced rate.
“MHAUS mourns the death of one of the pioneers in the study of Malignant Hyperthermia, Dr. Michael Denborough (July, 11, 1929 to February 8, 2014) of Australia, says MHAUS President Henry Rosenberg, M.D. Dr. Denborough and colleagues were the first to describe the disorder that was later named Malignant Hyperthermia. He did seminal work in describing the clinical and genetic basis for human MH. He also worked with pigs who developed “porcine stress syndrome” and showed how those animals could be a model for human MH. Later in his life he worked hard as an advocate for anti-nuclear proliferation. He was a great scientist, and a wonderful human being.”
Robert T. Dirksen, PhD, Department of Pharmacology and Physiology at University of Rochester Medical Center has been newly appointed to Chair the Professional Advisory Council (PAC) of the Malignant Hyperthermia Association of the United States (MHAUS).
Director of the Malignant Hyperthermia Investigation Unit at the Toronto General Hospital Sheila Riazi, MSc, MD, FRCPC has been newly appointed to the Professional Advisory Council (PAC) of the Malignant Hyperthermia Association of the United States (MHAUS).
Malignant Hyperthermia Experts from throughout Canada and the world will be attending the MH Scientific Conference in Toronto sponsored by the Malignant Hyperthermia Association of the United States in in conjunction with Toronto General Hospital Orlando on November 1 & 2, 2013.
There is mounting evidence that some people who are susceptible to Malignant hyperthermia (MH) will develop MH when exposed to hot environments or with exercise. This is could be problematic because without proper and prompt treatment, mortality associated with MH is extremely high; according to the Malignant Hyperthermia Association of the United States.
The 2013 Malignant Hyperthermia (MH) Scientific Conference is being held at the Chestnut Conference Centre, University of Toronto, Canada on November 1st and 2nd, 2013 and is sponsored by Malignant Hyperthermia Association of the United States (MHAUS) in conjunction with the University of Toronto. To register or for more information call: 011-1-607-674-7901, or email: [email protected].
The Malignant Hyperthermia Association of the United States (MHAUS) is very pleased to announce that Dr. Ron Litman, Professor of Anesthesiology and Critical Care at the Hospital of the University of Pennsylvania and the Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine has agreed to become the new Medical Director of the MH Hotline.
Learn the basics on how recognize, diagnose, and treat Malignant Hyperthermia by attending at the “MH Let’s Save a Life” conference where patients sit side-by-side with healthcare professionals, students, and families learning about MH from experts affiliated with MHAUS on September 14, 2013 from 10 am - 4 pm at St. Peter’s Health Partners - St. Peter’s Hospital located in Albany, NY. The inherited muscle disorder Malignant Hyperthermia (MH) is most often triggered by certain anesthetic drugs leading to a life-threatening crisis that requires prompt, specific treatment. In rare cases, MH may also be triggered by heat and exercise. The conference is sponsored by Malignant Hyperthermia Association of the United States in conjunction with St. Peter's Heath Partners: St. Peter’s Hospital, Albany Memorial, Samaritan Hospital and St. Mary's Hospital.
Learn the basics on how recognize, diagnose, and treat Malignant Hyperthermia by attending at the “MH Let’s Save a Life” conference where patients sit side-by-side with healthcare professionals, students, and families learning about MH from experts affiliated with MHAUS on September 14, 2013 from 10 am - 4 pm at St. Peter’s Health Partners - St. Peter’s Hospital located in Albany, NY. The inherited muscle disorder Malignant Hyperthermia (MH) is most often triggered by certain anesthetic drugs leading to a life-threatening crisis that requires prompt, specific treatment. In rare cases, MH may also be triggered by heat and exercise. The conference is sponsored by Malignant Hyperthermia Association of the United States in conjunction with St. Peter's Heath Partners: St. Peter’s Hospital, Albany Memorial, Samaritan Hospital and St. Mary's Hospital.
Orlando Health, the Florida Society of PeriAnesthesia Nurses, and the Florida Society of Anesthesiologists took a moment to comment on a conference they are co-sponsoring with the Malignant Hyperthermia Association of the United States in Orlando on June 29.
There is mounting evidence that some people who are susceptible to Malignant hyperthermia (MH) will develop MH when exposed to hot environments or with exercise. This is could be problematic because without proper and prompt treatment, mortality associated with MH is extremely high.
Six year-old Vincent Groetzner died June 14, 2010 when he quickly developed a fever that soared to 108 degrees after playing at a friend's house. The medical examiner reported the cause to be Malignant Hyperthermia (MH). MH is a condition caused by a gene mutation that can result in a sudden high temperature and severe muscle contractions, and in some cases death. Most often it occurs when a person receives certain types of anesthesia during surgery, but in very rare cases it also can be triggered by high outside temperatures or strenuous exercise, according to the Malignant Hyperthermia Association of the United States. Learn the basics on how recognize, diagnose, and treat Malignant Hyperthermia by attending at the “MH Let’s Save a Life” conference where patients sit side-by-side with healthcare professionals, students, and families learning about MH from experts affiliated with MHAUS on June 29, 2013 from 10 am - 4 pm at Orlando Regional Medical Center.
Learn the basics on how recognize, diagnose, and treat Malignant Hyperthermia by attending at the “MH Let’s Save a Life” mini-conference where patients sit side by side with healthcare professionals, students, and families learning about MH from experts affiliated with MHAUS on June 29, 2013 from 10 am - 4 pm at Orlando Regional Medical Center located in Orlando, FL. The inherited muscle disorder Malignant Hyperthermia (MH) is most often triggered by certain anesthetic drugs leading to a life-threatening crisis that requires prompt, specific treatment. In rare cases, MH may also be triggered by heat and exercise. The conference is sponsored by Malignant Hyperthermia Association of the United States in conjunction with Orlando Health, Florida Society of PeriAnesthesia Nurses (FLASPAN), and Florida Society of Anesthesiologists (FSA).
The Geoff Keller Chapter Group of the Malignant Hyperthermia Association of the United States announced today a concert remember the life of namesake Geoff Keller with his family and friends and build awareness about Malignant Hyperthermia. The concert is set for April 21, 2013 at 6:30 PM at the First United Methodist Church, 116 North East Perry Avenue. Featured is Walter Stout, a noted organist who holds a PhD in organ performance. Parking is located between the Church and Main Street. Additional parking is located across Perry Avenue. MHAUS Board Members will be on hand to talk about Malignant Hyperthermia and answer questions about this fast-acting potentially fatal disorder triggered by certain types of anesthesia. The concert is in a series of concerts to entertain, inspire, memorialize, and make us all aware of the difference we can make, and support MH education and preparedness.
MHAUS is accepting comments until March 31, 2013 about Noonan Syndrome Increasing Malignant Hyperthermia Susceptibility. Review of the medical literature does not support a correlation between Noonan syndrome and malignant hyperthermia (MH) susceptibility. There are no known contraindications to the use of volatile anesthetics and/or triggering agents in Noonan syndrome patients. Background: Noonan syndrome is often described as a “Male Turner syndrome” presenting with pterygium colli, short stature, pectus excavatum, webbed neck, down-slanting palpebral fissures and eyelid ptosis, and congenital heart disease (most commonly, pulmonary artery valvular stenosis). King-Denborough syndrome presents with a very similar phenotypic appearance and has a known link to MH susceptibility. There is a commonly held belief that patients with Noonan syndrome also have increased susceptibility to MH (Benca and Hogan, 2009).
The Malignant Hyperthermia Association of the United States proclaims March to be Malignant Hyperthermia Awareness and Training Month as a way to remind us that a Malignant Hyperthermia crisis is best managed with preparation. Malignant Hyperthermia is often experienced in individuals undergoing, what was expected to be, routine surgery but can also happen to a person outside of the operating room. Malignant Hyperthermia is an autosomal dominant genetic disorder found in an estimated 1 out of 2,000 people. Once triggered, the rapid progressive series of chain events include a body temperature of up to 107 degrees, muscle rigidity, system-wide organ failure, and possible death. Introduction of a treatment drug and advances in the understanding of MH have saved many lives since the syndrome was first described in the 1960s.
The Geoff Keller Chapter Group of the Malignant Hyperthermia Association of the United States announced today a concert to celebrate the life of namesake Geoff Keller with his family and friends and build awareness about Malignant Hyperthermia. The concert is set for March 13, 2013 at 6:30 PM at The Glenn Memorial United Methodist Church, Emory Campus, 1660 North Decatur Road, Atlanta, GA. Featured are "The Druid Hills Billys”, a Bluegrass band comprised of Atlanta-based doctors. Dinner served at 5:30 for $5 to concert-goers. Free parking at the Fishburne Parking Deck, 1672 North Decatur, or the Youth Activities Building, 1669 North Decatur.
Malignant Hyperthermia Association of the United States welcomes Georgirene Vladutiu Ph.D. of State University of New York at Buffalo to the MHAUS Board of Directors. Dr. Vladutiu is Professor of Pediatrics, Neurology and Pathology & Anatomical Sciences at the State University of New York at Buffalo where she is the Director of the Robert Guthrie Biochemical & Molecular Genetics Laboratory at the Buffalo General Medical Center . Dr. Vladutiu earned her Ph.D. at the University at Buffalo and is Board-certified in Clinical Biochemical Genetics. In her role as director of the Guthrie lab she is responsible for oversight of the performance of over 5,000 specialized tests to determine inborn errors of metabolism each year.
New video on how to handle a Malignant Hyperthermia crisis is now available from the Malignant Hyperthermia Association of the United States. The nine chapter DVD is set up for easy discussion and includes...
In order to establish such a service several obstacles had to be overcome. First and foremost a group of experts familiar with Malignant Hyperthermia had to be identified. The experts had to be willing to be available on a rotation schedule to answer calls.
The inherited muscle disorder Malignant Hyperthermia (MH) is most often triggered by certain anesthetic drugs leading to a life-threatening crisis that requires prompt, specific treatment. In rare cases, MH may also be triggered by heat and exercise. Learn the basics on how recognize, diagnose, and treat Malignant Hyperthermia by attending this conference for patients, healthcare professionals, students, and families taking place on November 10, 2012
This conference is for patients, healthcare professionals, students, and family, families and the public interested in the basics on how recognize, diagnose, and treat Malignant Hyperthermia.
From the MHAUS President’s Blog by MHAUS President, Henry Rosenberg, MD. A few months ago, I received a call from the MH Hotline who connected me to an anesthesiologist and OR team who were desperately trying to manage a Malignant Hyperthermia crisis. They were frantic and clearly trying to stabilize a patient experiencing a severe MH episode. The patient was an athletic older teenager undergoing an elective orthopedic surgical procedure on the ankle. Anesthesia was being conducted with the commonly used gas anesthetic sevoflurane and Succinylcholine had not been used...
Malignant Hyperthermia (MH) is an inherited muscle disorder most often triggered by certain anesthetic drugs leading to a life-threatening crisis that requires prompt, specific treatment. In rare cases, MH may also be triggered by heat and exercise. Healthcare professionals, patients, families and friends can learn the basics on how recognize, diagnose, and treat Malignant Hyperthermia at a one-day conference happening from 10 am to 4 pm September 22, 2012 at Froedtert & the Medical College of Wisconsin.
Malignant Hyperthermia (MH) is an inherited muscle disorder most often triggered by certain anesthetic drugs leading to a life-threatening crisis that requires prompt, specific treatment. In rare cases, MH may also be triggered by heat and exercise. Healthcare professionals, patients, families and friends can learn the basics on how recognize, diagnose, and treat Malignant Hyperthermia at a one-day conference happening from 10 am to 4 pm July 28, 2012 at Santa Fe Community College located in Santa Fe, New Mexico.
Moving patients suspected to have malignant hyperthermia to a hospital is just one of the topics discussed at the May 24th online live presentation for ambulatory surgical center healthcare professionals and administrative staff hosted by MHAUS and presented by Mohanad Shukry, M.D.
Moving patients suspected to have malignant hyperthermia to a hospital is just one of the topics discussed at the March 26 online live presentation for ambulatory surgical center healthcare professionals and administrative staff hosted by MHAUS and presented by Ronald S. Litman, MD of the Children’s Hospital of Philadelphia and MH Hotline Consultant.
Malignant hyperthermia (MH) is a life-threatening genetic muscle disorder, most commonly triggered in those at risk by certain types of drugs used during anesthesia. Heat stroke, on the other hand, most commonly occurs in individuals in response to physical exertion in hot/humid environments. While their common triggers may differ, the signs associated with MH and heat stroke are remarkably similar – uncontrolled muscle contractions, dangerous increases in body temperature, and muscle breakdown leading to the release of toxins in the blood which may cause cardiac arrhythmias and death. Immediate treatment for these conditions is crucial. Each year many individuals die or suffer consequences of heat stroke. Heat stroke is not uncommon in the military as well as in athletic competitions. This would be the first demonstration that a medication can be effective in preventing certain forms of heat stroke.
Malignant hyperthermia (MH) is a potentially life-threatening inherited disorder of muscle. Patients who are at risk for MH usually have no outward signs of muscle problems. However, when exposed to certain commonly used general anesthetics they may develop very high body temperature, increased heart rate and muscle breakdown. If not recognized and treated promptly MH may be fatal.
Medical professionals, patients and families can learn the basics on how recognize, diagnose, and treat Malignant Hyperthermia at a one-day Malignant Hyperthermia conference happening from 10 am to 4 pm June 4 at The Ottawa Hospital Civic Campus located in Ottawa Ontario.
Medical professionals, patients and families can learn the basics on how recognize, diagnose, and treat Malignant Hyperthermia at a one-day Malignant Hyperthermia conference happening from 10 am to 4 pm June 25 at Lake Receptions located in Mt. Dora, Florida.
Preparation is the best plan for Malignant Hyperthermia emergencies, and The Malignant Hyperthermia Association of the United States will be at the Ambulatory Surgery Center Annual Meeting, May 19-22, to answer questions about how medical facilities can best prepare for an MH emergency.
MHAUS announces availability of a $1,500 Travel Award to anesthesia resident/fellow or anesthesiologist who is within five years of ending his/her training to attend the 2010 annual meeting of the American Society of Anesthesiologists in San Diego CA.
Two winners have been selected for the Promising New Investigators Travel Scholarship Awards given annually by the Neuroleptic Malignant Syndrome Information Service (NMSIS).
Travel Award Available to share data with Clinicians and Scientists to advance the diagnosis, treatment, and management of Malignant Hyperthermia-Susceptible Patients April 23-24, 2010 at Mercy Hospital University of Pittsburgh Medical Center.
When the anesthesia care provider yells the code “Malignant Hyperthermia!” during a routine surgery there are approximately 15 minutes to save this patient’s life, you are excited but not panicking--- why?
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right